Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia (HEMOS AML 0106)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00510939
Recruitment Status : Unknown
Verified August 2009 by University of Bologna.
Recruitment status was:  Recruiting
First Posted : August 3, 2007
Last Update Posted : August 14, 2009
Janssen-Cilag Ltd.
Information provided by:
University of Bologna

No Study Results Posted on for this Study
  Recruitment Status : Unknown
  Primary Completion Date : No date given
  Study Completion Date : No date given